Shuimu Molecule
水木分子
Shuimu Molecule is an AI-driven drug discovery company spun out of Tsinghua University's Institute for AI Industry Research (AIR), founded by and chief-scientist-led by Professor Zaiqing Nie, a Tsinghua Wanguo Data Professor and AIR chief researcher who previously led Microsoft's academic search and natural-language-understanding platform LUIS and served as chief scientist for Alibaba's Tmall Genie . The company runs a dual-wheel model: proprietary pipeline development plus tool empowerment for the broader industry . Its product stack includes the ChatDD AI-agent framework for human-machine collaborative drug R&D, the OpenBioMed open-source platform (with 45 initial skills across biochemistry, protein analysis, single-cell omics, and data retrieval), and the consumer-facing ChatDDFM®-powered "Shuimu Zhiliao" life-sciences super-brain that offers tiered service from layperson explanations to expert-level knowledge-graph access . On the pipeline side, Shuimu Molecule has brought in Dr. Pan Qi—a twenty-year veteran across target discovery through clinical translation—as biopharmaceutical chief scientific officer to build its first in-house program in autoimmune disease, using AI-designed bispecific antibodies to block dual signaling pathways, with wet-lab validation underway . The company has partnerships with 30-plus branded enterprises as of 2025, with annual order growth exceeding 100% that year and a client pipeline of over 100, and has begun tool-export efforts in East Asia with broader global expansion planned . Dalton Venture is among its investors .
AI-generated — may contain errors, please verify.
Coverage
Exclusive Interview with Professor Nie Zaiqing: Is the Biopharma Version of "AI Lobster" Here? Shuimu Molecular's Dual-Wheel Model of "Proprietary Pipeline + Tool Empowerment" | Tong's Family
An **AIR incubated company and Tongtou Family portfolio company**, **Shuimu Molecular** has emerged as one of the most promising benchmark enterprises in AI-driven drug discovery, pursuing a dual-engine strategy of "tool empowerment + proprietary pipeline development." Its core achievements include the ChatDD intelligent agent framework, the OpenBioMed open-source platform, Shuimu Zhiliao — a new consumer-facing "super brain" tool for life sciences — and multimodal large models.
Steady Steps Toward Renewal, Momentum Into Waves | DTX 2025 Annual Review
Those who walk deeper into the cycle always spot the next beam of light.
Dalton Venture's Sun Qi: Focus, Steady Rhythm, Multiple Paths — Actively Positioning Through the Cycle | Dalton Insights
On July 3–4, 2025, **the 19th China Fund Partners Conference, co-hosted by Zero2IPO and PEDaily, was held in Shanghai**. This year's gathering brought together capital leaders to discuss industry trends, examine the latest dynamics in China's LP market, and explore the path forward for venture capital in a new cycle. **Dalton Venture founding and managing partner Sam Sun was invited to join the roundtable forum *"Cycle Positioning, Investment Strategies"*** to exchange views with fellow guests on the evolution of investment cycles and responsive strategies.
Riding the Wind, Breaking Boundaries — Tides Surge in Hong Kong | Dalton Venture 2025 CEO Summit Successfully Concludes
At the intersection of technological revolution and industrial transformation, what should be the starting point for the globalization of the life sciences industry? Where should mainland Chinese healthcare innovators set their first foothold for overseas expansion? Against a backdrop of intensifying international competition and sustained policy tailwinds, is Hong Kong — a city that blends international perspective with institutional advantages — emerging as the bridge for tech ventures to reach the world?
Steadfast Progress, Grounded in Action | Dalton Venture's 2024 Year in Review
Looking back at 2024, "adjustment" and "patience" became the defining keywords for venture capital. Yet on the long-distance track of life sciences and medtech, Dalton Venture kept moving forward with steady, deliberate strides. We navigated market fluctuations, caught glimpses of innovation, and helped companies take root and grow through the cycles — writing a new chapter of innovation-driven development with the power of capital.
21st Century Business Herald Interview | Dalton Venture's Sun Qi: Healthcare Is a Long, Snowy Slope — Time for Systematic Bets Is Here
In recent years, as the healthcare industry has yet to emerge from the capital winter, most investment firms have grown more cautious. Dalton Venture, however, has remained active on the investment front thanks to its distinctive strategy and deep understanding of the sector. Recently, **Sun Qi, founding and managing partner of Dalton Venture, sat down with 21st Century Business Herald for an exclusive interview, sharing his unique insights into healthcare industry trends and his confidence and determination to navigate through cycles.**
